title: Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90.
abstract: A full account of an asymmetric synthesis of reblastatin (1) and the first total synthesis of autolytimycin (2) and related structural compounds is described. The syntheses expand the utility of a highly regio- and diastereoselective hydrometalation aldehyde addition sequence to assemble the fully functionalized ansa chain of the natural products. Also documented is an intramolecular copper-mediated amidation reaction to close the 19-membered macrolactams. The amidation reaction was also employed for the generation of structural derivatives (6-9) of phenolic ansamycins. Ansamycin natural products and selected structural analogues were evaluated in a competitive binding assay to breast cancer cell lysate and a cytotoxicity assay. Both reblastatin (1) and autolytimycin (2) were shown to bind the heat shock protein 90 with enhanced binding activity (approximately 25 nM) than 17-allylamino-17-demethoxygeldanamycin (17-AAG, 4), a geldanamycin (3) derivative currently under evaluation for treatment of cancer (approximately 100 nM).
authors.affiliation: Department of Chemistry and Center for Chemical Methodology and Library Development (CMLD-BU), Metcalf Center for Science and Engineering, 590 Commonwealth Avenue, Boston University, Boston, Massachusetts 02215, USA.
authors.forename: Iwona E
authors.initials: IE
authors.lastname: Wrona
authors.forename: Alexander
authors.initials: A
authors.lastname: Gozman
authors.forename: Tony
authors.initials: T
authors.lastname: Taldone
authors.forename: Gabriela
authors.initials: G
authors.lastname: Chiosis
authors.forename: James S
authors.initials: JS
authors.lastname: Panek
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D016227:Benzoquinones / Q000737:chemistry; D045744:Cell Line, Tumor; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D047029:Lactams, Macrocyclic / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D015394:Molecular Structure; D010636:Phenols / Q000138:chemical synthesis; D011809:Quinones / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D010636:Phenols; D011809:Quinones; C551125:autolytimycin; C414123:reblastatin; C004532:quinone
references.citation: J Antibiot (Tokyo). 1970 Sep;23(9):442-7
references.pmid: 5459626
references.citation: J Biol Chem. 2002 Jul 12;277(28):25480-5
references.pmid: 11983711
references.citation: Biochemistry. 2006 May 2;45(17):5678-85
references.pmid: 16634649
references.citation: Bioorg Med Chem Lett. 2006 Sep 1;16(17):4515-8
references.pmid: 16797988
references.citation: J Comb Chem. 2005 Sep-Oct;7(5):673-81
references.pmid: 16153061
references.citation: Curr Top Med Chem. 2006;6(11):1205-14
references.pmid: 16842157
references.citation: Angew Chem Int Ed Engl. 2006 Feb 13;45(8):1276-9
references.pmid: 16425327
references.citation: Angew Chem Int Ed Engl. 2005 Feb 11;44(8):1223-5
references.pmid: 15654683
references.citation: J Med Chem. 2006 Jul 27;49(15):4606-15
references.pmid: 16854066
references.citation: J Am Chem Soc. 2007 Jan 10;129(1):38-9
references.pmid: 17199277
references.citation: Chem Biol. 2003 Apr;10(4):361-8
references.pmid: 12725864
references.citation: Cell. 1997 Jul 11;90(1):65-75
references.pmid: 9230303
references.citation: J Med Chem. 2010 Jan 14;53(1):3-17
references.pmid: 20055425
references.citation: Org Lett. 2000 Feb 24;2(4):497-9
references.pmid: 10814360
references.citation: Chemistry. 2002 Apr 15;8(8):1778-84
references.pmid: 11933105
references.citation: Curr Cancer Drug Targets. 2003 Oct;3(5):325-30
references.pmid: 14529384
references.citation: J Med Chem. 1999 Jan 28;42(2):260-6
references.pmid: 9925731
references.citation: Rev Physiol Biochem Pharmacol. 2004;151:1-44
references.pmid: 14740253
references.citation: Trends Mol Med. 2004 Feb;10(2):47-51
references.pmid: 15106614
references.citation: Angew Chem Int Ed Engl. 2003 Sep 5;42(34):3996-4028
references.pmid: 12973759
references.citation: J Antibiot (Tokyo). 2000 Nov;53(11):1310-2
references.pmid: 11213294
references.citation: J Antibiot (Tokyo). 1979 Aug;32(8):849-51
references.pmid: 500504
references.citation: J Med Chem. 2008 Sep 25;51(18):5494-7
references.pmid: 18800759
references.citation: J Am Chem Soc. 2005 Nov 2;127(43):15026-7
references.pmid: 16248632
references.citation: Org Lett. 2008 Jun 19;10(12):2477-9
references.pmid: 18489177
references.citation: J Mol Biol. 2007 Sep 14;372(2):287-97
references.pmid: 17662999
references.citation: Pharmacol Ther. 1998 Aug;79(2):129-68
references.pmid: 9749880
references.citation: Chembiochem. 2009 Jul 20;10(11):1801-5
references.pmid: 19554593
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1078-87
references.pmid: 15718306
references.citation: Trends Mol Med. 2002;8(4 Suppl):S55-61
references.pmid: 11927289
references.citation: J Am Chem Soc. 2002 Sep 25;124(38):11368-78
references.pmid: 12236752
references.citation: Cancer Chemother Pharmacol. 1998;42(4):273-9
references.pmid: 9744771
references.citation: Bioorg Med Chem Lett. 2008 Mar 1;18(5):1588-91
references.pmid: 18243703
references.citation: Chem Rev. 1999 May 12;99(5):1191-224
references.pmid: 11749444
references.citation: J Am Chem Soc. 1970 Dec 30;92(26):7591-3
references.pmid: 5490719
references.citation: J Antibiot (Tokyo). 2000 Jul;53(7):657-63
references.pmid: 10994806
references.citation: Bioorg Med Chem. 2004 Oct 15;12(20):5317-29
references.pmid: 15388159
references.citation: Angew Chem Int Ed Engl. 2007;46(4):572-5
references.pmid: 17036293
references.citation: Curr Cancer Drug Targets. 2003 Oct;3(5):377-83
references.pmid: 14529389
references.citation: Clin Cancer Res. 2004 Jul 15;10(14):4813-21
references.pmid: 15269157
references.citation: Ann Oncol. 2003 Aug;14(8):1169-76
references.pmid: 12881371
references.citation: Org Lett. 2003 May 29;5(11):1991-3
references.pmid: 12762704
references.citation: Mol Cancer Ther. 2004 Aug;3(8):1021-30
references.pmid: 15299085
references.citation: Eur J Biochem. 2000 Sep;267(17):5421-6
references.pmid: 10951200
references.citation: J Am Chem Soc. 2004 Mar 3;126(8):2425-30
references.pmid: 14982450
references.citation: Cancer Res. 2005 Nov 1;65(21):10006-15
references.pmid: 16267026
references.citation: Org Lett. 2005 May 12;7(10):2035-8
references.pmid: 15876048
references.citation: J Org Chem. 2006 Nov 10;71(23):8934-45
references.pmid: 17081025
references.citation: Chem Rev. 2008 Aug;108(8):3054-131
references.pmid: 18698737
references.citation: J Org Chem. 2007 Nov 23;72(24):9003-9
references.pmid: 17508763
references.citation: Biochem Pharmacol. 2003 Apr 1;65(7):1061-75
references.pmid: 12663042
references.citation: Org Lett. 2005 Apr 14;7(8):1529-32
references.pmid: 15816744
references.citation: Cell. 1997 Apr 18;89(2):239-50
references.pmid: 9108479
references.citation: Cancer Cell. 2003 Mar;3(3):213-7
references.pmid: 12676580
references.citation: J Org Chem. 2004 Nov 12;69(23):7822-9
references.pmid: 15527257
references.citation: J Am Chem Soc. 2007 Mar 21;129(11):3127-34
references.pmid: 17323946
references.citation: J Am Chem Soc. 2002 Jun 26;124(25):7421-8
references.pmid: 12071751